CTGF

A potential therapeutic target for Bronchopulmonary dysplasia

Xinbao Wang, Hong Cui, Shu Wu

Research output: Contribution to journalReview article

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that often occurs in preterm infants. However, there is still no effective treatment for BPD. Recent studies demonstrated that connective tissue growth factor (CTGF) is involved in the development of BPD in experimental models. CTGF, also known as CCN2, is the second member of the CCN family and is necessary for normal lung development. The expression of CTGF is increased in lung tissues in infants with BPD. Hyperoxia, inflammation and mechanic ventilation increase CTGF expression which may promote fibroblast proliferation, matrix production and vascular remodeling. Conditional overexpression of CTGF in alveolar epithelial type II cells disrupts alveolarization and vascular development, induces vascular remodeling, and results in pulmonary hypertension, the pathological hallmarks of severe BPD. Further studies have shown that inhibition of CTGF by a CTGF monoclonal antibody improved alveolarization and vascular development, and decreased pulmonary vascular remodeling and pulmonary hypertension in a rodent model of BPD induced by hyperoxia. CTGF may be a novel target for BPD therapy in preterm infants.

Original languageEnglish (US)
Article number172588
JournalEuropean Journal of Pharmacology
Volume860
DOIs
StatePublished - Oct 5 2019
Externally publishedYes

Fingerprint

Connective Tissue Growth Factor
Bronchopulmonary Dysplasia
Hyperoxia
Therapeutics
Pulmonary Hypertension
Premature Infants
Lung
Blood Vessels
Alveolar Epithelial Cells
Lung Diseases
Ventilation
Rodentia
Chronic Disease
Theoretical Models
Fibroblasts
Monoclonal Antibodies
Inflammation

Keywords

  • Bronchopulmonary dysplasia
  • Connective tissue growth factor
  • Therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

CTGF : A potential therapeutic target for Bronchopulmonary dysplasia. / Wang, Xinbao; Cui, Hong; Wu, Shu.

In: European Journal of Pharmacology, Vol. 860, 172588, 05.10.2019.

Research output: Contribution to journalReview article

@article{b32014a6f469477ea242a4d90a97550e,
title = "CTGF: A potential therapeutic target for Bronchopulmonary dysplasia",
abstract = "Bronchopulmonary dysplasia (BPD) is a chronic lung disease that often occurs in preterm infants. However, there is still no effective treatment for BPD. Recent studies demonstrated that connective tissue growth factor (CTGF) is involved in the development of BPD in experimental models. CTGF, also known as CCN2, is the second member of the CCN family and is necessary for normal lung development. The expression of CTGF is increased in lung tissues in infants with BPD. Hyperoxia, inflammation and mechanic ventilation increase CTGF expression which may promote fibroblast proliferation, matrix production and vascular remodeling. Conditional overexpression of CTGF in alveolar epithelial type II cells disrupts alveolarization and vascular development, induces vascular remodeling, and results in pulmonary hypertension, the pathological hallmarks of severe BPD. Further studies have shown that inhibition of CTGF by a CTGF monoclonal antibody improved alveolarization and vascular development, and decreased pulmonary vascular remodeling and pulmonary hypertension in a rodent model of BPD induced by hyperoxia. CTGF may be a novel target for BPD therapy in preterm infants.",
keywords = "Bronchopulmonary dysplasia, Connective tissue growth factor, Therapy",
author = "Xinbao Wang and Hong Cui and Shu Wu",
year = "2019",
month = "10",
day = "5",
doi = "10.1016/j.ejphar.2019.172588",
language = "English (US)",
volume = "860",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - CTGF

T2 - A potential therapeutic target for Bronchopulmonary dysplasia

AU - Wang, Xinbao

AU - Cui, Hong

AU - Wu, Shu

PY - 2019/10/5

Y1 - 2019/10/5

N2 - Bronchopulmonary dysplasia (BPD) is a chronic lung disease that often occurs in preterm infants. However, there is still no effective treatment for BPD. Recent studies demonstrated that connective tissue growth factor (CTGF) is involved in the development of BPD in experimental models. CTGF, also known as CCN2, is the second member of the CCN family and is necessary for normal lung development. The expression of CTGF is increased in lung tissues in infants with BPD. Hyperoxia, inflammation and mechanic ventilation increase CTGF expression which may promote fibroblast proliferation, matrix production and vascular remodeling. Conditional overexpression of CTGF in alveolar epithelial type II cells disrupts alveolarization and vascular development, induces vascular remodeling, and results in pulmonary hypertension, the pathological hallmarks of severe BPD. Further studies have shown that inhibition of CTGF by a CTGF monoclonal antibody improved alveolarization and vascular development, and decreased pulmonary vascular remodeling and pulmonary hypertension in a rodent model of BPD induced by hyperoxia. CTGF may be a novel target for BPD therapy in preterm infants.

AB - Bronchopulmonary dysplasia (BPD) is a chronic lung disease that often occurs in preterm infants. However, there is still no effective treatment for BPD. Recent studies demonstrated that connective tissue growth factor (CTGF) is involved in the development of BPD in experimental models. CTGF, also known as CCN2, is the second member of the CCN family and is necessary for normal lung development. The expression of CTGF is increased in lung tissues in infants with BPD. Hyperoxia, inflammation and mechanic ventilation increase CTGF expression which may promote fibroblast proliferation, matrix production and vascular remodeling. Conditional overexpression of CTGF in alveolar epithelial type II cells disrupts alveolarization and vascular development, induces vascular remodeling, and results in pulmonary hypertension, the pathological hallmarks of severe BPD. Further studies have shown that inhibition of CTGF by a CTGF monoclonal antibody improved alveolarization and vascular development, and decreased pulmonary vascular remodeling and pulmonary hypertension in a rodent model of BPD induced by hyperoxia. CTGF may be a novel target for BPD therapy in preterm infants.

KW - Bronchopulmonary dysplasia

KW - Connective tissue growth factor

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85070263671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070263671&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2019.172588

DO - 10.1016/j.ejphar.2019.172588

M3 - Review article

VL - 860

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

M1 - 172588

ER -